SCHEMBL6788652

SCHEMBL6788652

CCOC(=O)c1[nH]nc2c1c(Br)c(Br)c1[nH]ncc12

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.40
ALDH1A1 P00352 2/20 0.40
KMT2A Q03164 2/20 0.40
MEN1 O00255 1/20 0.40
DUSP3 P51452 1/20 0.38
PDE4B Q07343 1/20 0.36
HSD17B10 Q99714 3/20 0.36
AURKA O14965 1/20 0.35
MAPK10 P53779 1/20 0.35
RIPK1 Q13546 1/20 0.35
KDM4E B2RXH2 2/20 0.35
PDE4D Q08499 1/20 0.35
POLB P06746 1/20 0.34
HPGD P15428 1/20 0.33
CDC25B P30305 1/20 0.33
TUBB4A P04350 1/20 0.33
TUBB P07437 1/20 0.33
TUBA3C P0DPH7 1/20 0.33
TUBA1B P68363 1/20 0.33
TUBA4A P68366 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6797679 0.71 CCNA2 (0.63) MAPTALDH1A1KMT2AMEN1DUSP3
SCHEMBL15509199 0.70 ALDH1A1 (0.53) MAPTALDH1A1KMT2AMEN1DUSP3
SCHEMBL15230490 0.68 PDE4D (0.56) MAPTALDH1A1KMT2AMEN1DUSP3
SCHEMBL6787887 0.68 MAPT (0.47) MAPTALDH1A1DUSP3HSD17B10AURKA
SCHEMBL19253412 0.67 MAPT (0.55) MAPTALDH1A1KMT2AMEN1DUSP3
SCHEMBL5698452 0.67 KDM4E (0.44) MAPTALDH1A1HSD17B10AURKAMAPK10
SCHEMBL11577717 0.66 KMT2A (0.56) MAPTALDH1A1KMT2AMEN1PDE4B
SCHEMBL15659148 0.66 ALDH1A1 (0.56) ALDH1A1KMT2AMEN1HSD17B10KDM4E
SCHEMBL26103568 0.66 MAPT (0.47) MAPTALDH1A1KMT2AMEN1DUSP3
SCHEMBL15850521 0.65 KMT2A (0.54) MAPTALDH1A1KMT2AMEN1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040127492-A1 Cyclic pyrazoles for the inhibition of mitogen activated protein kinase-activated protein kinase-2 PHARMACIA CORPORATION 2004-07-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040127492-A1 Cyclic pyrazoles for the inhibition of mitogen activated protein kinase-activated protein kinase-2 MKNK2, MAPKAPK2, MAP3K2 MAPT 3143/4885ALDH1A1 4449/4885KMT2A 1257/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.